Association Between Glucocorticoids Treatment and Viral Clearance Delay in Patients with COVID-19: A Systematic Review and Meta-Analysis

Jianbo Li  
West China Hospital, Sichuan University

Xuelian Liao  
West China Hospital, Sichuan University

Yue Zhou  
West China Hospital, Sichuan University

Luping Wang  
West China Hospital, Sichuan University

Hang Yang  
West China Hospital, Sichuan University

Wei Zhang  
West China Hospital, Sichuan University

Zhongwei Zhang  
West China Hospital, Sichuan University

Yan Kang (kangyan@scu.edu.cn)  
Department of Intensive Care Unit, West China Hospital of Sichuan University  
https://orcid.org/0000-0003-4968-1217

Research article

Keywords: COVID-19, glucocorticoids treatment, viral clearance delay

Posted Date: March 29th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-138544/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background Evidence of glucocorticoids on viral clearance delay of COVID-19 patients is not clear.

Methods In this systematic review and meta-analysis, we searched studies on Medline, Embase, EBSCO, ScienceDirect, Web of Science, Cochrane Library, and ClinicalTrials.gov from 2002 to December 2, 2020. We mainly pooled the adjusted hazard ratios (HRs), mean difference (MD) or risk ratios (RRs) of viral clearance delay and did subgroup analyses by doses and the severity of illness.

Results One trial and 38 observational studies, with a total of 7119 patients, were identified. Glucocorticoids treatment was associated with delayed viral clearance in COVID-19 (Adjusted HR 1.71, 95% CI 1.51 to 1.94, I²=22%, PI 1.45 to 2.01), based on moderate-quality evidence. In subgroup analyses, risk of viral clearance delay was significantly higher among COVID-19 patients being mild or moderate ill (adjusted HR 1.94, 95% CI 1.39 to 2.70, I²=52%; MD 2.59, 95% CI 1.21 to 3.97, I²=24%), but not in those of being severe or critical ill (adjusted HR 1.85, 95% CI 1.05 to 3.26; MD 0.22, 95% CI -1.85 to 2.29, I²=56%); taking high doses (adjusted HR 1.49, 95% CI 1.03 to 2.15; unadjusted RR 1.47, 95% CI 1.12 to 1.94) rather than taking low doses (adjusted HR 1.39, 95% CI 0.93 to 2.08; unadjusted RR 1.33, 95% CI 1.00 to 1.77) or pulse (unadjusted RR 1.85, 95% CI 0.66 to 5.19).

Conclusions Glucocorticoids treatment delayed viral clearance in COVID-19 patients of being mild or moderate ill or taking a high dose, rather in those of being severe or critical ill or taking low dose or pulse.

Introduction

Historically, glucocorticoids were widely recommended to treat SARS, but this proved to be controversial. A recent large randomized controlled trial (RCT) from the United Kingdom compared 2104 hospital COVID-19 patients who were given dexamethasone with those of 4321 patients who were not. Results from this large trial showed glucocorticoid treatment cut the risk of death from 40% to 28% for patients on ventilators and from 25% to 20% for patients needing oxygen. Then, a systematic review and meta-analysis involving 7 RCTs also revealed a significant association between glucocorticoids treatment and decreased mortality in COVID-19 patients of critical illness. Although these results are encouraging, glucocorticoids theoretically delay virus removal. At present, no study has systematically assessed glucocorticoids treatment effects on viral clearance for COVID-19. Thus, we conducted this systematic review and meta-analysis to evaluate this potential effect from glucocorticoids treatment for COVID-19.

Methods

Guidance and Protocol

We reported our study according to standards of the meta-analysis of observational studies in epidemiology (MOOSE) and preferred reporting items for systematic reviews and meta-analyses.
We registered our protocol for this review and meta-analysis on PROSPERO (CRD42020194225).

**Eligibility criteria and definitions**

We considered criteria of eligible studies as follows: participants were COVID-19 patients infected with SARS-CoV-2 confirmed through the nucleic acid test; the intervention was glucocorticoids, no matter types, and doses; the controls were COVID-19 patients receiving usual care except glucocorticoids treatment; the outcomes should involve viral clearance, no matter what kind of data was presented. Both RCTs and observational studies (including cohort studies, case-control studies, case series of more than 10 patients) were included. Viral clearance delay was defined as the opposite of SARS-CoV-2 RNA shedding at any time from illness onset (different studies were based on different time frames, usually at ≥7-day from illness onset) and the SARS-CoV-2 RNA shedding was defined as two consecutive RNA negative with at least 24-h intervals and the date of the first negative test was defined as the day of viral RNA clearance.

**Literature search**

Two of the authors (JB.L. and XL.L.) conducted a literature search on several databases: Medline (Ovid), Embase (Ovid), EBSCO (H.W. Wilson: OmniFile Full-Text Mega), ScienceDirect, Web of Science (All database), Cochrane Library, and ClinicalTrials.gov from 2019 to December 2, 2020. Also, we reviewed reference lists of identified studies, systematic reviews, and review articles on the same topic. Language or publication status was not restricted. Supplementary Table 1 showed the details of the search strategy.

**Study selection**

After duplicates were removed, the title and abstract of each item were browsed to screen studies with eligible participants and intervention by two independent groups of four authors (H.Y. and W.Z.; Y.Z. and LP.W.). Further screening was conducted to determine whether the item met the rest eligibility criteria. Disagreements were resolved by consensus, and if necessary, consultation with a third author (ZW.Z.).

**Data collection process**

Data from included studies were extracted into standard collection forms and information tables for quality assessment were created. The quantile estimation method was applied to estimate the sample mean and standard deviation if a study presented summary statistics as median, first and third quartiles, and sample size. Note that if the study reported a hazard ratio (HR) of SARS-CoV-2 RNA shedding rather than viral clearance delay, then an HR of viral clearance delay was obtained by taking the reciprocal of the HR i.e.1/ HR and associated confidence interval (CI).

**Assessment of risk of bias**
The Newcastle-Ottawa-Scale (NOS)\(^5\) for observational studies and using the Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) were used to assess the risk of bias by two independent groups of four authors (H.Y. and W.Z.; Y.Z. and LP.W.). Each domain of NOS was composed of 2 to 4 items of criteria, and each criterion was scored in the form of stars. A total score of 8 or 9 was assessed as low risk of bias, 6 or 7 as some concerns, and \(\leq 5\) as high risk. Each domain of RoB 2 was assessed as low risk, some concerns, or a high risk of bias. The study's overall risk of bias was determined by the highest risk of bias for any criteria. Disagreements were resolved by consensus, and if necessary, consultation with a third author (ZW.Z.).

**Data synthesis**

Statistical analyses were performed using the meta package in R (version 4.0.1; The R Project for Statistical Computing). We mainly used HRs and their associated 95% CI to assess outcomes, as well as a prediction interval (PI) for the effect of future studies based on the present\(^6\). Adjusted HRs and unadjusted HRs were separately pooled. If provided, we also pooled odds ratios (ORs), risk ratios (RRs) (for 2x2 table data) for binary data, and mean difference (MD) for continuous data. We used random-effects models to pool data. The \(I^2\) test was used to examine heterogeneity and \(I^2 \geq 50\%\) was considered as significant heterogeneity. A 2-tailed \(P\) value of less than 0.05 was statistically significant. Funnel plots and the Egger test were adopted to assess the publication bias of the main results.

**Subgroup analysis**

We planned several subgroup analyses according to the following variables: (1) severity of illness (mild or moderate and severe or critical); (2) doses (equivalent methylprednisolone) of glucocorticoids (low dose [40 mg/day], high dose [80 mg/day], and pulse [250-500 mg/day]). The severity of illness was reported by the studies following Chinese interim guidelines for diagnosis and treatment for COVID-19 patients (version 7.0)\(^7,8\).

**Sensitivity analysis**

We conducted sensitivity analyses on main results from adjusted HRs by (1) excluding the study with the largest sample, (2) excluding the study with the smallest sample, (3) excluding studies of case-control design, (4) excluding studies of retrospective cohort design, (5) excluding studies identified by influence analyses\(^9\), (5) excluding studies with the non-low risk of bias.

**Results**

**Eligible studies and study characteristics**

Of the 6055 records, 39 studies\(^10-38\) involving a total of 7119 patients were included in the final meta-analysis (Figure 1). Table 1 showed the characteristics of the included studies. These studies, with a size from 33 to 774 and a median age from 42 to 64, comprised 1 RCT, 11 case-control studies, and 17
retrospective cohort studies. One of the studies came from Brazil, one from Spain, and the rest from China. Most studies used a low dose of glucocorticoids, i.e. 1-2 mg/kg/d (an equivalent of methylprednisolone) and only one study\(^{29}\) reported pulse use of glucocorticoids, i.e. 250-500 mg/d (an equivalent of methylprednisolone). Methylprednisolone was the most common type, followed by dexamethasone, prednisone and prednisolone, and finally hydrocortisone. The median days for glucocorticoids treatment from illness onset ranged from 1 to 13 days and the median duration of treatment from 3 to 10.8 days. The studies reported different time frames of viral clearance delay, between 5- and 45-day, and the longest reported follow-up was 50 days.

Supplementary Tables 1, 2, and 3 showed the risk bias of the included studies. Seven studies were considered as low risk, 19 as some concerns, and 3 as high risk. The average score of total risk bias for case-control studies was 6.1 and the average score for retrospective cohort studies was 6.7. The only RCT was assessed as the trial with the risk bias of some concerns, due to its deviations from intended interventions.

**Risk of viral clearance delay**

A total of nine studies reported HR for risk of viral clearance delay in COVID-19 patients who received glucocorticoids treatment, of which the longest follow-up was 50 days. The overall unadjusted HR (1.58, 95% CI 1.39 to 1.80, \(I^2=13\%), PM 1.32 to 1.90) (Figure 2B) and adjusted HR (1.71, 95% CI 1.51 to 1.94, \(I^2=22\%), PM 1.45 to 2.01) (Figure 2A) revealed an association between glucocorticoids treatment and increased risk of viral clearance delay in COVID-19 patients. The pooled MD of days for SARS-CoV-2 RNA shedding from illness onset (2.13, 95% CI 0.83 to 3.42, \(I^2=73\%), PM -2.66 to 6.92) (Figure 2C) and overall unadjusted RR (1.29, 95% CI 1.14 to 1.47, \(I^2=58\%), PM 0.86 to 1.95) (Figure 3C) also confirmed the delayed viral clearance in glucocorticoids treatment patients, compared to patients revived non-glucocorticoids treatment. A few studies (four studies)\(^{24,31,34,36}\) reported the ORs for risk of viral clearance delay, however, the time frames of viral clearance delay among these studies were substantially different (Li&Cao et al\(^{24}\), 11-day; Xu&Chen et al\(^{34}\), 15-day; Qi&Yang et al\(^{31}\), 17-day; Yan&Liu et al\(^{36}\), 23-day) (Table 1). Pooled unadjusted OR (2.08, 95% CI 0.35 to 12.41, \(I^2=84\%\)) (Figure 3B) and adjusted OR (1.82, 95% CI 0.70 to 4.76, \(I^2=57\%), PM 0.04 to 81.84) (Figure 3A) of these studies showed no association between glucocorticoids treatment and risk of viral clearance delay.

Influence analyses identified four studies\(^{15,23,26,32}\), with an excessive influence on the overall results, of which two studies with extreme sample size are the excluded studies of predesign in the sensitivity analyses (Supplementary Figure 8). All the sensitivity analyses based on adjusted HRs showed a similar result with that from the main analysis (Supplementary Figure 1-7). Funnel plot analysis showed no asymmetry on the HRs, RRs, and MDs (Supplementary Figure 9-12), and the Egger test detected no significant small-study effects. Due to a very limited number of studies reporting ORs, we failed to draw funnel plots and correspondingly failed to conduct Egger tests on these studies.

**Subgroup analysis**
Subgroup analysis revealed that risk of viral clearance delay was significantly higher in glucocorticoids-treated COVID-19 patients of being mild or moderate (adjusted HR 1.94, 95% CI 1.39 to 2.70, I²=52%; MD 2.59, 95% CI 1.21 to 3.97, I²=24%), but not patients of being severe or critical (adjusted HR 1.85, 95% CI 1.05 to 3.26; MD 0.22, 95% CI -1.85 to 2.29, I²=56%) (Figure 4). Only one study compared the risk of viral clearance delay between COVID-19 patients who received a low dose (40 mg/day, an equivalent of methylprednisolone) and those who received a high dose (80 mg/day), and another study reported the effects of the pulse (250-500 mg/day) use of glucocorticoids. Their results indicated that a high dose of glucocorticoids increased the risk of viral clearance delay (adjusted HR 1.49, 95% CI 1.03 to 2.15; unadjusted RR 1.47, 95% CI 1.12 to 1.94), but neither low dose (adjusted HR 1.39, 95% CI 0.93 to 2.08; unadjusted RR 1.33, 95% CI 1.00 to 1.77) nor pulse use (unadjusted RR 1.85, 95% CI 0.66 to 5.19) (Figure 5).

Discussion

In this meta-analysis of 39 studies (at moderate risk of bias involving 7119 patients), glucocorticoids treatment was significantly associated with an increased risk of viral clearance delay in COVID-19 patients. Subgroup analyses demonstrated that among glucocorticoids-treated COVID-19 patients, the detrimental effect in our outcomes was associated with patients of being mild or moderate, but not patients of being severe or critical. Evidence also indicated a high dose, but not low dose or pulse use of glucocorticoids substantially lead to viral clearance delay. Though only one RCT was included, however, adjusted data from observational studies and low heterogeneity of pooled data ensured the power of conclusions.

Principal findings and comparison with other studies

As of writing this manuscript (early December 2020), no meta-analysis has examined the use of glucocorticoids in patients with COVID-19 regarding viral clearance delay. Most trials of glucocorticoids suspended enrollment after the RECOVERY trial which was the globally largest one and drew an encouraging conclusion of reduction in mortality of COVID-19. However, as one kind of immunosuppressant, glucocorticoids’ detrimental effect-one of the most important side effects, i.e. viral clearance delay-had not been further investigated in these trials. Thus, information about its impact on the humoral immune response against the virus is in need. Most previous experience with patients infected by SARS, MERS, and H1N1 indicated that glucocorticoids delayed viral RNA clearance. Nevertheless, one study on factors promoting the prolonged shedding of H1N1 indicated a significant association of viral clearance delay and delayed antiviral therapy, but not glucocorticoids treatment. However, glucocorticoids treatment usually delayed antiviral therapy for two or more days after symptom onset and thus might have a more indirect role on the viral clearance delay. Evidence is inconsistent on the viral clearance delay of glucocorticoids-treated COVID-19 patients. The most focus of the debate is the potential confounding role of doses and the severity of illness on the associations. Our meta-analysis pooled confounders-adjusted HRs and conducted subgroup analyses by doses and the severity of illness.
The findings of our meta-analysis of the association of glucocorticoids administration with delayed viral RNA clearance were in line with the recently published results on COVID-19. We further discovered this association occurred in mild or moderate patients but not severe or critical patients; occurred in patients receiving a high dose, but not low dose or pulse use of glucocorticoids.

**Strengths and limitations**

This systematic review and meta-analysis have several methodological strengths. We pooled data in their original form and focused on the results of pooling adjusted HRs which could avoid time-varying confounding and as well as other potential confounders. Thus, the heterogeneity of main pooled results was low and the overall risk of bias was moderate. To further take the between-study variance into account, we provided prediction intervals to expect the effects of future studies to fall based on our present evidence in the meta-analysis. To exam the robustness of our main results, we conducted a series of presumable sensitivity analyses, in which extreme values were detected by influence analysis and then excluded to avoid distortion of our pooled effect estimate. Moreover, we assessed potential high-risk subgroups by doses and the severity of illness, which was the main concern of glucocorticoids administration.

Our study has limitations. First, the results of this meta-analysis were main from observational studies and clinical heterogeneity was inevitable. Though the heterogeneity was low when we pooled time-effect-containing HRs, the heterogeneity of other pooled effects (MDs, ORs, RRs) was moderate-to-high. The main heterogeneity came from different time-frame among studies that reported non-time-effect-containing effects, such as ORs or RRs (2x2 table). Moreover, we failed to investigate the heterogeneity among studies that reported MDs due to limited data of confounders. Besides, the role of duration, timing, and types of glucocorticoids treatment on the viral clearance delay has not been further investigated due to insufficient accuracy of the information or lack of uniformity between studies.

**Implications for practice**

Through, people who have a lot of experience with glucocorticoids in the treatment of inflammatory, little information could be obtained regarding its role on the humoral immune response against the virus. Many years ago, one trial involving 29 normal adult males showed that short courses (3 or 5 days) of high dose (96 mg/d) methylprednisolone could decrease serum IgG concentration. Theoretically, the reduction in antibody production might delay viral clearance and experience a high-risk of reinfection. However, there was one study that demonstrated that dexamethasone treatment did not affect the formation of pneumococcal antibodies during community-acquired pneumonia. Viral pneumonia should be different from bacterial pneumonia. Previous studies on H1N1, SARS, MERS has shown glucocorticoids’ negative effects on viral clearance, however, the evidence is sporadic. We did the first meta-analysis to systematically investigate glucocorticoids’ role on viral clearance delay of SARS-CoV-2. Our conclusion indicated glucocorticoids might delay viral clearance in mild or moderate patients and patients taking a high dose, but not severe or critical patients, and not in patients taking low dose or
pulse. We believe our findings would further bring light to the current clinical practice in glucocorticoids treatment of COVID-19.

Conclusions

The findings suggest that glucocorticoids treatment delayed viral clearance in COVID-19 patients of being a mild or moderate illness, but not in those of being severe or critical. Moreover, it seems that patients taking high doses rather than taking low doses or pulse would experience a high-risk of viral clearance delay.

List Of Abbreviations

COVID-19, coronavirus disease 2019; SARS, severe acute respiratory syndrome; RCT, randomized controlled trial; MOOSE, meta-analysis of observational studies in epidemiology; PRISMA, preferred reporting items for systematic reviews and meta-analyses; NOS, Newcastle-Ottawa-Scale; HRs, hazard ratios; ORs, odds ratios; RRs, risk ratios; MD, mean difference; CI, confidence interval; PI, prediction interval.

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

Additional data are available from the corresponding author on reasonable request at kangyan@scu.edu.cn.

Competing interests

All the authors declared no competing interests.

Funding

This work is supported by the Project of Novel Coronavirus Pneumonia in West China Hospital (HX2019nCoV027). The study's funders had no role in the design and conduct of the study, data collection, data analysis, data interpretation, or writing of the report.

Authors' contributions
JB.L., ZW.Z., and YK conceived the study and designed the protocol. JB.L. and XL.L. performed the literature search. HY, WZ, YZ, and LP.W. selected the studies, exacted the relevant information, and assessed the risk of bias of included studies. JB.L. synthesized the data and wrote the first draft of the paper. All authors contributed to critically revising successive drafts and approved the final version. JB.L., ZW.Z., and Y.K. are guarantors. The corresponding authors avouch that all listed authors meet authorship criteria and that no other qualified authors have been omitted.

Acknowledgments

We thank Longhao Zhang (Chinese Evidence-based Medicine Centre, West China Hospital, Sichuan University) for his support in methodological suggestions for this meta-analysis.

References

1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. *The New England journal of medicine* 2020.
2. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. *JAMA* 2020.
3. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**(15): 2008-12.
4. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009; **339**(7716): b2535.
5. Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. [http://wwwohrola/programs/clinical_epidemiology/oxfordhtm](http://wwwohrola/programs/clinical_epidemiology/oxfordhtm) (accessed April 3, 2020).
6. IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. Plea for routinely presenting prediction intervals in meta-analysis. *BMJ Open* 2016; **6**(7): e010247.
7. National Health Commission. Chinese clinical guidance for COVID-19 pneumonia diagnosis and treatment (7th edition). [http://kjfymeetingchinaorg/msite/news/show/cn/3337html](http://kjfymeetingchinaorg/msite/news/show/cn/3337html); 2020.
8. Peng FJ, Tu L, Yang YS, et al. Management and treatment of COVID-19: The Chinese experience. *Can J Cardiol* 2020; **36**(6): 915-30.
9. Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. *Res Synth Meth* 2010; **1**(2): 112-25.
10. Chang D, Zhao P, Zhang DW, et al. Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19. *Journal of Allergy and Clinical Immunology: In Practice* 2020; **8**(8): 2585.
11. Chen Q, Song Y, Wang L, et al. Corticosteroids treatment in severe patients with COVID-19: a propensity score matching study. *Expert review of respiratory medicine* 2020.
12. Chen XD, Zhu BY, Hong WX, et al. Associations of clinical characteristics and treatment regimens with viral RNA shedding duration in patients with COVID-19. *International Journal of Infectious Diseases* 2020; 98: 252-60.

13. Ding C, Feng XW, Chen YF, et al. Effect of corticosteroid therapy on the duration of SARS-CoV-2 clearance in patients with mild COVID-19: A retrospective cohort study. *Infectious diseases and therapy* 2020.

14. Fang XW, Mei Q, Yang TJ, et al. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. *Journal of Infection* 2020; 81(1): 147-9.

15. Feng ZC, Li J, Yao SH, et al. Clinical factors associated with progression and prolonged viral shedding in COVID-19 patients: A multicenter study. *Aging and disease* 2020; 11(5): 1069-81.

16. Fu HY, Luo Y, Gao JP, et al. Effects of short-term low-dose glucocorticoids for patients with mild COVID-19. *BioMed research international* 2020; 2020.

17. Gong Y, Guan L, Jin Z, Chen SX, Xiang GM, Gao BA. Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID-19 patients under 50 years old. *Journal of medical virology* 2020.

18. Hu FY, Yin G, Chen YP, et al. Corticosteroid, oseltamivir, and delayed admission are independent risk factors for prolonged viral shedding in patients with Coronavirus Disease 2019. *The clinical respiratory journal* 2020.

19. Hu ZG, Li SJ, Yang AL, et al. Delayed hospital admission and high-dose corticosteroids potentially prolong SARS-CoV-2 RNA detection duration of patients with COVID-19. *European journal of clinical microbiology & infectious diseases* 2020.

20. Huang R, Zhu CW, Wang J, et al. Corticosteroid therapy is associated with the delay of SARS-CoV-2 clearance in COVID-19 patients. *European Journal of Pharmacology* 2020: 173556.

21. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase IIb, placebo-controlled trial. *Clinical Infectious Diseases* 2020.

22. Ji JJ, Zhang JX, Shao ZY, Xie QF, Zhong L, Liu ZF. Glucocorticoid therapy does not delay viral clearance in COVID-19 patients. *Critical care* 2020; 24(1): 565.

23. Li Q, Li WX, Jin YP, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: A retrospective cohort study. *Infectious diseases and therapy* 2020.

24. Li TZ, Cao ZH, Chen Y, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. *Journal of Medical Virology* 2020.

25. Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chinese medical journal* 2020; 133(9): 1039-43.

26. Liu J, Zhang S, Dong X, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. *The Journal of clinical investigation* 2020; 130(12): 6417-28.
27. Liu ZB, Li X, Fan GH, et al. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. *Clinical Microbiology and Infection* 2020.

28. Ma YM, Zeng HH, Zhan ZJ, et al. Corticosteroid use in the treatment of COVID-19: A multicenter retrospective study in Hunan, China. *Frontiers in pharmacology* 2020; **11**: 1198.

29. Masia M, Fernandez-Gonzalez M, Garcia JA, Padilla S, Gutierrez F. Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19. *Journal of Infection* 2020.

30. Ni Q, Ding C, Li YT, et al. Effect of low-to-moderate dose glucocorticoids on viral clearance in COVID-19: a retrospective study. *Chinese Journal of Clinical Infectious Diseases* 2020; **13**(1): 21-4.

31. Qi L, Yang Y, Jiang DX, et al. Factors associated with the duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study. *International Journal of Infectious Diseases* 2020; **96**: 531-7.

32. Shi D, Wu WR, Wang Q, et al. Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study. *The Journal of infectious diseases* 2020.

33. Wu CM, Hou DN, Du CL, et al. Corticosteroid therapy for coronavirus disease 2019-related acute respiratory distress syndrome: a cohort study with propensity score analysis. *Critical care* 2020; **24**(1): 643.

34. Xu KJ, Chen YF, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clinical Infectious Diseases* 2020.

35. Xue J, Zheng J, Shang XY, et al. Risk factors for prolonged viral clearance in adult patients with COVID-19 in Beijing, China: A prospective observational study. *International Immunopharmacology* 2020; **89**: 107031.

36. Yan D, Liu XY, Zhu YN, et al. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. *The European respiratory journal* 2020; **56**(1).

37. Yuan ML, Xu XX, Xia DP, et al. Effects of corticosteroid treatment for non-severe COVID-19 pneumonia: A propensity score-based analysis. *Shock* 2020.

38. Zuo Y, Liu YL, Zhong Q, Zhang K, Xu YH, Wang ZX. Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID-19: A retrospective study in two designated hospitals in Anhui, China. *Journal of medical virology* 2020; **92**(11): 2666-74.

39. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. *American journal of respiratory and critical care medicine* 2018; **197**(6): 757-67.

40. Cao B, Gao H, Zhou B, et al. Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia. *Critical care medicine* 2016; **44**(6): e318-28.
41. Lee N, Chan K, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *Journal of Clinical Virology* 2004; 31(4): 304-9.

42. Ryoo SM, Kim WY, Sohn CH, et al. Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days. *Influenza Other Respir Viruses* 2013; 7(5): 833-7.

43. Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis in R: A hands-on guide; 2019.

44. Butler WT, Rossen RD. Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. *The Journal of clinical investigation* 1973; 52(10): 2629-40.

45. Van Mens SP, Meijvis SC, Grutters JC, Vlaminckx BJ, Bos WJ, Rijkers GT. Dexamethasone treatment has no effect on the formation of pneumococcal antibodies during community-acquired pneumonia. 2012; 19(5): 811-3.

**Figures**
Figure 1

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for the Article Selection Process
Figure 2

Forest Plot of Hazard Ratios and Mean Differences for Risk of Viral Clearance Delay
Figure 3

Forest Plot of Odds Ratios and Risk Ratios for Risk of Viral Clearance Delay
**Figure 4**

Subgroup Analysis by Severity of Illness

| Study                  | Size | aHR | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| **Mild or moderate**  |      |     |            |            |          |
| Feng&Li, 2020         | 495  | 1.69| [1.32; 2.17]|           | 55.9     |
| Li&Li, 2020           | 475  | 2.39| [1.61; 3.54]|           | 28.6     |
| **Subtotal (random effect)** | 1.94 | [1.39; 2.70] |           | 84.5     |

Heterogeneity: $I^2 = 52\%, p = NA$

**Severe or critical**

| Study                  | Size | aHR | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| Feng&Li, 2020         | 69   | 1.85| [1.05; 3.26]|           | 15.5     |

Heterogeneity: $I^2 = NA\%, p = .15$

**Total (random effect)**

| Study                  | Size | aHR | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| **Subtotal (random effect)** | 1.85 | [1.05; 3.26] |           | 15.5     |
| **Total (random effect)** | 1.89 | [1.49; 2.40] |           | 100.0    |

Prediction interval

Heterogeneity: $I^2 = 5\%, p = .35$
Test for overall (random effect): $z = 5.30 (p < .001)$
Test for between-subgroup-differences (random effect): $\chi^2 = 0.02, df = 1 (p = .89)$

| Study                  | Size | MD  | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| **Mild or moderate**  |      |     |            |            |          |
| Ding&Feng, 2020       | 82   | 3.10| [0.57; 5.63]|           | 10.5     |
| Fang&Mei, 2020        | 55   | -1.10| [-5.00; 2.80]|           | 7.6      |
| Fu&Luo, 2020          | 33   | 3.80| [0.15; 7.45]|           | 8.1      |
| Ji&Zhang, 2020        | 490  | 0.03| [-5.52; 5.58]|           | 5.2      |
| Li&Li, 2020           | 475  | 4.53| [2.10; 6.95]|           | 10.7     |
| Ma&Zeng, 2020         | 368  | 2.85| [0.13; 5.57]|           | 10.0     |
| Ni&Ding, 2020         | 28   | 1.27| [-2.13; 4.67]|           | 8.6      |
| **Subtotal (random effect)** | 2.59 | [1.21; 3.97] |           | 60.7     |

Heterogeneity: $I^2 = 24\%, p = .06$

**Severe or critical**

| Study                  | Size | MD  | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| Chen&Song, 2020       | 371  | -1.14| [-2.80; 0.52]|           | 12.4     |
| Fang&Mei, 2020        | 23   | 0.50| [-3.55; 4.55]|           | 7.4      |
| Ji&Zhang, 2020        | 180  | 7.52| [0.56; 14.48]|           | 3.8      |
| Ma&Zeng, 2020         | 82   | 5.90| [-1.81; 13.61]|          | 3.2      |
| Wu&Hou, 2020          | 382  | -1.09| [-2.66; 0.48]|           | 12.6     |
| **Subtotal (random effect)** | 0.22 | [-1.85; 2.29] |           | 39.3     |

Heterogeneity: $I^2 = 56\%, p = .25$

**Total (random effect)**

| Study                  | Size | MD  | 95% CI     | 95% CI     | Weight % |
|-----------------------|------|-----|------------|------------|----------|
| **Subtotal (random effect)** | 0.22 | [-1.85; 2.29] |           | 100.0    |
| **Total (random effect)** | 1.66 | [0.09; 3.24] |           | 100.0    |

Prediction interval

Heterogeneity: $I^2 = 68\%, p < .001$
Test for overall (random effect): $z = 2.07 (p = .04)$
Test for between-subgroup-differences (random effect): $\chi^2 = 3.49, df = 1 (p = .06)$
Figure 5

Subgroup Analysis by Doses of Glucocorticoids

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SFig1.SensitivityAnalysesExcludingLargestSample.pdf
- SFig2.SensitivityAnalysesExcludingSmallestSample.pdf
